Patient, disease, and treatment characteristics of patients with ALL treated on DFCI ALL protocols
| . | All patients N = 388 . | Normal BMI group, n = 207 . | Overweight/obese BMI groups, n = 181 . | P value . |
|---|---|---|---|---|
| Age group (2 groups) | <.001 | |||
| 15-29 y | 254 (65) | 164 (79) | 90 (50) | |
| 30-50 y | 134 (35) | 43 (21) | 91 (50) | |
| Age group (4 groups) | <.001 | |||
| 15-19 y | 138 (36) | 100 (48) | 38 (21) | |
| 20-29 y | 116 (30) | 64 (31) | 52 (29) | |
| 30-39 y | 72 (19) | 20 (10) | 52 (29) | |
| 40-49 y | 62 (16) | 23 (11) | 39 (22) | |
| Sex (male) | 240 (62) | 117 (56) | 123 (68) | .021 |
| Immunophenotype∗ | .75 | |||
| B-ALL | 288 (74) | 155 (75) | 133 (73) | |
| T-ALL | 100 (26) | 52 (25) | 48 (27) | |
| Anterior mediastinal mass | 77 (20) | 42 (20) | 35 (19) | .96 |
| CNS involvement | .70 | |||
| CNS1 | 303 (78) | 165 (80) | 138 (76) | |
| CNS2 | 43 (11) | 23 (11) | 20 (11) | |
| CNS3 | 13 (3) | 6 (3) | 7 (4) | |
| Traumatic/unknown | 29 (8) | 13 (6) | 16 (9) | |
| WBC (×109/L, median, IQR) | 11.8 (4.1-45.2) | 11.95 (4-46.8) | 11.55 (4.9-44.4) | .94 |
| Cytogenetics | ||||
| Normal | 102 (26) | 55 (27) | 47 (26) | .89 |
| t(9;22) | 48 (12) | 14 (7) | 34 (19) | <.001 |
| Complex | 12 (3) | 6 (3) | 6 (3) | .82 |
| Hyperdiploid | 39 (10) | 29 (14) | 10 (6) | .006 |
| MLL | 24 (6) | 12 (6) | 12 (7) | .73 |
| Other abnormalities | 122 (31) | 69 (33) | 53 (29) | .39 |
| Unknown | 51 (13) | 27 (13) | 24 (13) | .95 |
| Treatment type | .24 | |||
| On trial | 308 (79) | 169 (82) | 139 (77) | |
| Per protocol | 80 (21) | 38 (18) | 42 (23) | |
| Protocols | .12 | |||
| Older (00-001 & 01-175) | 127 (33) | 75 (36) | 52 (29) | |
| Newer (05-001 & 06-254)/as per newer protocols | 261 (67) | 132 (64) | 129 (71) |
| . | All patients N = 388 . | Normal BMI group, n = 207 . | Overweight/obese BMI groups, n = 181 . | P value . |
|---|---|---|---|---|
| Age group (2 groups) | <.001 | |||
| 15-29 y | 254 (65) | 164 (79) | 90 (50) | |
| 30-50 y | 134 (35) | 43 (21) | 91 (50) | |
| Age group (4 groups) | <.001 | |||
| 15-19 y | 138 (36) | 100 (48) | 38 (21) | |
| 20-29 y | 116 (30) | 64 (31) | 52 (29) | |
| 30-39 y | 72 (19) | 20 (10) | 52 (29) | |
| 40-49 y | 62 (16) | 23 (11) | 39 (22) | |
| Sex (male) | 240 (62) | 117 (56) | 123 (68) | .021 |
| Immunophenotype∗ | .75 | |||
| B-ALL | 288 (74) | 155 (75) | 133 (73) | |
| T-ALL | 100 (26) | 52 (25) | 48 (27) | |
| Anterior mediastinal mass | 77 (20) | 42 (20) | 35 (19) | .96 |
| CNS involvement | .70 | |||
| CNS1 | 303 (78) | 165 (80) | 138 (76) | |
| CNS2 | 43 (11) | 23 (11) | 20 (11) | |
| CNS3 | 13 (3) | 6 (3) | 7 (4) | |
| Traumatic/unknown | 29 (8) | 13 (6) | 16 (9) | |
| WBC (×109/L, median, IQR) | 11.8 (4.1-45.2) | 11.95 (4-46.8) | 11.55 (4.9-44.4) | .94 |
| Cytogenetics | ||||
| Normal | 102 (26) | 55 (27) | 47 (26) | .89 |
| t(9;22) | 48 (12) | 14 (7) | 34 (19) | <.001 |
| Complex | 12 (3) | 6 (3) | 6 (3) | .82 |
| Hyperdiploid | 39 (10) | 29 (14) | 10 (6) | .006 |
| MLL | 24 (6) | 12 (6) | 12 (7) | .73 |
| Other abnormalities | 122 (31) | 69 (33) | 53 (29) | .39 |
| Unknown | 51 (13) | 27 (13) | 24 (13) | .95 |
| Treatment type | .24 | |||
| On trial | 308 (79) | 169 (82) | 139 (77) | |
| Per protocol | 80 (21) | 38 (18) | 42 (23) | |
| Protocols | .12 | |||
| Older (00-001 & 01-175) | 127 (33) | 75 (36) | 52 (29) | |
| Newer (05-001 & 06-254)/as per newer protocols | 261 (67) | 132 (64) | 129 (71) |
BMI groups were calculated per CDC guidelines.
CDC, Center for Disease Control; CNS, central nervous system; IQR, interquartile range 25% to 75%; MLL, mixed lineage leukemia.
One and 3 patients were diagnosed with T-/myeloid and B-/myeloid mixed phenotype acute leukemia, respectively.